Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda

Executive Summary

A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.

You may also be interested in...



Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.

Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes

Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents

The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings

Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry

Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement

Related Content

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel